Physician profile
Yuval Patel
NPI 1609106210
$47,171.94
in general payments reported to CMS, 2019-2025
24 companies · $22K in 2025
The $22K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $3,740 · 2021: $2,860 · 2023: $16K · 2024: $2,751 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Consulting Fee: $14K · Food and Beverage: $3,485 · Travel and Lodging: $1,595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,063.00 |
| Consulting Fee | $14,428.75 |
| Food and Beverage | $3,485.09 |
| Travel and Lodging | $1,595.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $19,173.65 | 2024-2025 | Rezdiffra, Resmetirom |
| Novo Nordisk INC | $19,116.25 | 2023-2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $6,615.35 | 2020-2024 | |
| Abbvie INC. | $412.97 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $272.27 | 2023-2025 | Xifaxan, Trulance, Plenvu |
| Pfizer INC. | $234.69 | 2024-2025 | |
| Lilly USA, LLC | $162.38 | 2024-2025 | Omvoh |
| Genzyme Corporation | $154.04 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $136.72 | 2023-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $133.63 | 2023-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $115.48 | 2024-2025 | Zenpep |
| Janssen Biotech, INC. | $115.40 | 2023-2025 | Stelara, Tremfya |
| Gilead Sciences, INC. | $93.27 | 2023-2025 | |
| Qol Medical, LLC | $85.62 | 2023-2024 | Sucraid, Sucraid |
| Alnylam Pharmaceuticals INC. | $73.13 | 2024-2025 | Givlaari |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $72.80 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $41.65 | 2024 | Voquezna |
| Evoke Pharma, INC. | $41.64 | 2024 | |
| Ardelyx, INC. | $38.10 | 2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $28.46 | 2023 | Dificid |
| Pharmacosmos Therapeutics INC. | $21.00 | 2023 | Monoferric |
| Celgene Corporation | $17.08 | 2023 | Zeposia |
| Ferring Pharmaceuticals INC. | $16.36 | 2024 | Rebyota |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuval Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.